A Single-arm Exploratory Study of Neoadjuvant Therapy

Status Recruiting

Clinical Trial Summary

Neoadjuvant EGFR TKI therapy targeting EGFR mutation has some problems failure to fulfill clinical requirements such as low MPR rate, tissue fibrosis and other major surgical impacts and unmet clinical needs.This study hypothesized that Tisleizumab combined with chemotherapy in the neoadjuvant treatment of stage II-IIIA non-squamous NSCLC with EGFR-mutant PD-L1 expression ≥1% could significantly improve the pathological response rate after neoadjuvant therapy, improve the surgical complete resection rate, reduce perioperative complications and do not increase the surgical difficulty.In this study, biomarker analysis is going to explore the possible direction of neoadjuvant therapy population screening, and to explore a possible method for the efficacy and safety of neoadjuvant immunotherapy in clinical stage II-IIIA non-squamous non-small cell lung cancer with EGFR mutation and expression of PD-L1.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05527808
Study type	Interventional
Source	Guangzhou Institute of Respiratory Disease
Contact	Henry liang, Dr
Phone	15625064712
Email	hengrui_liang@163.com
Status	Recruiting
Phase	N/A
Start date	August 1, 2022
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02898857` - Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma	N/A
Completed	`NCT02127359` - Whole-Exome Sequencing (WES) of Cancer Patients
Recruiting	`NCT01249066` - Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma	N/A
Not yet recruiting	`NCT04482829` - TCM in the Treatment of Lung Adenocarcinoma	N/A
Recruiting	`NCT04929041` - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Phase 2/Phase 3
Terminated	`NCT04691375` - A Study of PY314 in Subjects With Advanced Solid Tumors	Phase 1
Terminated	`NCT02621333` - Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma	Phase 2
Active, not recruiting	`NCT02282267` - Blood Detection of EGFR Mutation For Iressa Treatment	N/A
Not yet recruiting	`NCT01942629` - Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas	N/A
Recruiting	`NCT01482585` - Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy	N/A
Recruiting	`NCT03376737` - Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma	Phase 2
Recruiting	`NCT05537922` - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Recruiting	`NCT04937283` - Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm	N/A
Recruiting	`NCT06255197` - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Completed	`NCT02093000` - A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma	N/A
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1
Terminated	`NCT04682431` - A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05736991` - Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
Enrolling by invitation	`NCT05136014` - Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Terminated	`NCT05012397` - Milademetan in Advanced/Metastatic Solid Tumors	Phase 2